Received Apr 21, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
vaccination failure; facial herpes zoster; This serious case was reported by a nurse via sales rep and described the occurrence of vaccination failure in a female patient who received Herpes zoster (Shingrix) for prophylaxis. Co-suspect products included Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received the 2nd dose of Shingrix and the 1st dose of Shingrix. In FEB-2026, less than 2 years after receiving Shingrix and Shingrix, the patient experienced vaccination failure (Verbatim: vaccination failure) (serious criteria GSK medically significant) and facial herpes zoster (Verbatim: facial herpes zoster). The outcome of the vaccination failure and facial herpes zoster were not reported. It was unknown if the reporter considered the vaccination failure and facial herpes zoster to be related to Shingrix and Shingrix. The company considered the vaccination failure to be unrelated to Shingrix and Shingrix. It was unknown if the company considered the facial herpes zoster to be related to Shingrix and Shingrix. Additional Information: GSK Receipt Date: 07-APR-2026 Patient received both doses of Shingrix over a year ago and she had a case of shingles in late February 2026 on her face. The batch number was not provided, and we are unable to contact the reporter. This case was considered as suspected vaccination failure as details regarding time to onset for shingles and laboratory confirmation regarding shingles were unknown at the time of reporting.; Sender's Comments: A case of Vaccination failure, less than 2 years after receiving 2nd dose and 1st dose of Shingrix in a female patient. Case lacks further information on exact time to onset, medical history, concurrent conditions and laboratory confirmation. Based on the available information a possible causality that the event was caused by the GSK product cannot be ascertained. Consent for further follow-up has not been received.